Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + capecitabine (Emory University)
- Development stage
- Unknown
- Lead developer
- Emory University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This refers to a perioperative chemotherapy regimen being evaluated by Emory University in the Phase III clinical trial NCT03579758 for the treatment of incidental gallbladder cancer. The protocol involves a neoadjuvant phase consisting of gemcitabine and cisplatin, followed by surgical reoperation, and an adjuvant phase using capecitabine. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by targeting ribonucleoside reductase and incorporating into DNA, cisplatin is a platinum-based agent that induces DNA crosslinking, and capecitabine is an oral fluoropyrimidine carbamate that acts as a prodrug of 5-fluorouracil to inhibit thymidylate synthase. This combination strategy aims to improve outcomes in patients with T1b, T2, or T3 gallbladder cancer discovered incidentally during routine cholecystectomy.
- Other names
- Perioperative Chemotherapy for Incidental Gallbladder CancerEmory University Gallbladder Cancer Regimen
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on gemcitabine + cisplatin + capecitabine (Emory University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + capecitabine (Emory University).